DK1864998T4 - Bindingsmolekyler - Google Patents

Bindingsmolekyler Download PDF

Info

Publication number
DK1864998T4
DK1864998T4 DK07075586.3T DK07075586T DK1864998T4 DK 1864998 T4 DK1864998 T4 DK 1864998T4 DK 07075586 T DK07075586 T DK 07075586T DK 1864998 T4 DK1864998 T4 DK 1864998T4
Authority
DK
Denmark
Prior art keywords
binding molecules
molecules
binding
Prior art date
Application number
DK07075586.3T
Other languages
Danish (da)
English (en)
Other versions
DK1864998T3 (da
Inventor
Roger Kingdon Craig
Franklin Gerardus Grosveld
Richard Wilhelm Janssens
Dubravka Drabek
Original Assignee
Univ Erasmus Med Ct Rotterdam
Kingdon Craig R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35431831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1864998(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0416392A external-priority patent/GB2416768A/en
Priority claimed from GB0511881A external-priority patent/GB0511881D0/en
Application filed by Univ Erasmus Med Ct Rotterdam, Kingdon Craig R filed Critical Univ Erasmus Med Ct Rotterdam
Application granted granted Critical
Publication of DK1864998T3 publication Critical patent/DK1864998T3/da
Publication of DK1864998T4 publication Critical patent/DK1864998T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1143—Gag-pol proteins, e.g. p17or p24
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
DK07075586.3T 2004-07-22 2005-07-22 Bindingsmolekyler DK1864998T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0416392A GB2416768A (en) 2004-07-22 2004-07-22 Heavy chain immunoglobulin complexes
GB0511881A GB0511881D0 (en) 2005-06-10 2005-06-10 Binding molecules
EP05766644.8A EP1776383B1 (en) 2004-07-22 2005-07-22 Binding molecules

Publications (2)

Publication Number Publication Date
DK1864998T3 DK1864998T3 (da) 2014-01-13
DK1864998T4 true DK1864998T4 (da) 2022-07-04

Family

ID=35431831

Family Applications (3)

Application Number Title Priority Date Filing Date
DK07075586.3T DK1864998T4 (da) 2004-07-22 2005-07-22 Bindingsmolekyler
DK05766644.8T DK1776383T3 (da) 2004-07-22 2005-07-22 Bindingsmolekyler
DK10179784.3T DK2311874T3 (en) 2004-07-22 2005-07-22 binding Molecules

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK05766644.8T DK1776383T3 (da) 2004-07-22 2005-07-22 Bindingsmolekyler
DK10179784.3T DK2311874T3 (en) 2004-07-22 2005-07-22 binding Molecules

Country Status (21)

Country Link
US (7) US20090285805A1 (enExample)
EP (6) EP1776383B1 (enExample)
JP (3) JP2008512987A (enExample)
KR (4) KR101151957B1 (enExample)
CN (2) CN102659941B (enExample)
AU (2) AU2005263994B2 (enExample)
BR (1) BRPI0513577A (enExample)
CA (1) CA2580336C (enExample)
CY (2) CY1115762T1 (enExample)
DK (3) DK1864998T4 (enExample)
ES (3) ES2440990T5 (enExample)
HU (1) HUE034335T2 (enExample)
LT (1) LT2311874T (enExample)
MX (2) MX2007000921A (enExample)
PL (2) PL2311874T3 (enExample)
PT (2) PT2311874T (enExample)
RU (1) RU2398882C2 (enExample)
SG (1) SG188080A1 (enExample)
SI (2) SI2311874T1 (enExample)
WO (1) WO2006008548A2 (enExample)
ZA (3) ZA200701186B (enExample)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1776383B1 (en) * 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
GB0601513D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
TWI404727B (zh) * 2006-01-25 2013-08-11 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 對偶基因排除
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
GB0706628D0 (en) * 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
WO2009013620A2 (en) * 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
AU2008270274B2 (en) 2007-07-03 2012-06-28 Ablynx N.V. Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
CA2706425A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
ES2475201T3 (es) 2007-12-26 2014-07-10 Biotest Ag Agentes dirigidos contra CD138 y usos de los mismos
PL2242772T3 (pl) 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
US9446146B2 (en) 2007-12-26 2016-09-20 Biotest Ag Methods and agents for improving targeting of CD138 expressing tumor cells
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
EP2669298A3 (en) 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
LT2285408T (lt) 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
KR101711222B1 (ko) 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
CA2747644C (en) 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
WO2010079149A1 (de) 2009-01-09 2010-07-15 Ipk Gatersleben Fusionsantikörper
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
WO2011072204A1 (en) 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
HRP20251657T1 (hr) 2009-12-14 2026-02-13 Ablynx N.V. Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011133886A2 (en) * 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
EP2601298B1 (en) * 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
PY1147875A (es) 2010-11-08 2015-08-03 Novartis Ag Polipéptidos de enlace de los receptores de quimiocina
WO2012122512A1 (en) * 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9433620B2 (en) 2011-05-13 2016-09-06 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9409899B2 (en) 2012-02-13 2016-08-09 Cadila Healthcare Limited Process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexylmethanisoindol-1,3-dione and its intermediates
EP3517548A1 (en) * 2012-03-13 2019-07-31 NovImmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014093908A2 (en) 2012-12-14 2014-06-19 Omt, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
PL2967012T3 (pl) 2013-03-14 2021-04-19 Erasmus University Medical Center Rotterdam Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
CN105722855B (zh) * 2013-09-05 2021-04-23 Igm生物科学股份有限公司 恒定链经修饰的双特异性五价和六价Ig-M抗体
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
WO2015120474A1 (en) * 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CA2943242A1 (en) * 2014-03-21 2015-09-24 X-Body, Inc. Bi-specific antigen-binding polypeptides
SG10201808083VA (en) 2014-03-21 2018-10-30 Regeneron Pharma Vl antigen binding proteins exhibiting distinct binding characteristics
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
PL3140392T3 (pl) 2014-05-06 2023-11-27 F. Hoffmann-La Roche Ag Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków
PL3209698T5 (pl) 2014-10-22 2022-04-25 Crescendo Biologics Limited Mysz transgeniczna
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
RU2749674C2 (ru) 2015-07-29 2021-06-16 Аллерган, Инк. Антитела против ang-2, содержащие только тяжелую цепь
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3334762A1 (en) 2015-08-14 2018-06-20 Allergan, Inc. Heavy chain only antibodies to pdgf
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
CN109862784A (zh) * 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP3332637A1 (en) * 2016-12-09 2018-06-13 Universitätsklinikum Hamburg-Eppendorf Vhh-containing heavy chain antibody and production thereof
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CA3050715A1 (en) 2017-01-19 2018-07-26 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
KR20190141695A (ko) 2017-04-13 2019-12-24 센티 바이오사이언시스, 인코포레이티드 병용 암 면역요법
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
US20200207867A1 (en) 2017-09-13 2020-07-02 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
SG11202005692WA (en) 2017-12-20 2020-07-29 Harbour Biomed Shanghai Co Ltd Antibodies binding ctla-4 and uses thereof
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
AU2019241350B2 (en) 2018-03-30 2025-10-02 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
KR102115300B1 (ko) 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
US12110321B2 (en) * 2018-06-11 2024-10-08 Aarhus Universitet Single domain antibodies for complement regulation
JP7572861B2 (ja) 2018-06-13 2024-10-24 クリスタル バイオサイエンス インコーポレイテッド 遺伝子変換による自律型重鎖可変ドメインの改変による抗体の産生
LT3823990T (lt) 2018-07-20 2026-04-10 TeneoTwo, Inc. Antikūnai iš sunkiosios grandinės, besirišantys prie cd19
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
WO2020052543A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cd33 and constructs thereof
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2020087065A1 (en) 2018-10-26 2020-04-30 Teneobio, Inc. Heavy chain antibodies binding to cd38
CN113874394B (zh) 2019-02-20 2024-01-19 和铂抗体有限公司 抗体
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
US20220227888A1 (en) 2019-06-07 2022-07-21 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
WO2021041920A1 (en) * 2019-08-28 2021-03-04 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
BR112022011824A2 (pt) 2019-12-18 2022-08-30 Teneofour Inc Anticorpos de cadeia pesada que se ligam a cd38
GB202003632D0 (en) 2020-03-12 2020-04-29 Harbour Antibodies Bv SARS-Cov-2 (SARS2, COVID-19) antibodies
KR20250007022A (ko) 2020-04-29 2025-01-13 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
WO2021222616A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Methods of treating multiple myeloma
CA3184351A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
IL299027A (en) 2020-06-30 2023-02-01 Teneobio Inc Multispecific antibodies that bind BCMA
WO2022002063A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 一种4-1bb结合蛋白及其应用
CN116193985A (zh) * 2020-07-13 2023-05-30 加拿大商木曾路生物科技公司 表达重链抗体的转基因动物
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
GB202017555D0 (en) 2020-11-06 2020-12-23 Harbour Antibodies Bv Antibody-conjugated nanoparticles
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
MX2023006573A (es) 2020-12-03 2023-06-19 Amgen Inc Constructos de inmunoglobulina con multiples dominios de union.
JP7822400B2 (ja) * 2020-12-09 2026-03-02 トリアンニ，インコーポレーテッド 重鎖のみ抗体
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
EP4294834A2 (en) 2021-02-19 2023-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Single domain antibodies that neutralize sars-cov-2
WO2022183074A2 (en) 2021-02-25 2022-09-01 Teneobio, Inc. Anti-psma antibodies and car-t structures
MX2023009882A (es) 2021-02-26 2023-08-30 Teneobio Inc Anticuerpos anti-muc1-c y estructuras car-t.
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
PE20260568A1 (es) 2021-04-06 2026-03-10 Teneobio Inc Anticuerpos anti-cd19 y estructuras car-t
CN117337303A (zh) 2021-04-16 2024-01-02 特尼奥生物股份有限公司 抗cd20抗体及car-t结构
EP4333614A4 (en) * 2021-05-05 2025-04-09 Leveragen, Inc. MANIPULATED NON-HUMAN ANIMALS TO PRODUCE ANTIBODIES
CN117651486A (zh) * 2021-05-05 2024-03-05 利威瑞健股份有限公司 用于生产抗体的工程改造的非人动物
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen
WO2023036982A1 (en) 2021-09-10 2023-03-16 Harbour Antibodies Bv Anti-sars2-s antibodies
GB202112935D0 (en) 2021-09-10 2021-10-27 Harbour Antibodies Bv Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
EP4598958A1 (en) 2022-10-05 2025-08-13 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
US20260103529A1 (en) 2022-10-18 2026-04-16 Confo Therapeutics N.V. Amino Acid Sequences Directed Against the Melanocortin 4 Receptor and Polypeptides Comprising the Same for the Treatment of MC4R-Related Diseases and Disorders
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
TW202602940A (zh) 2024-04-09 2026-01-16 美商安進公司 激動性抗ｉｌ－２ｒｂｇ重鏈抗體
GB202406483D0 (en) 2024-05-09 2024-06-26 Harbour Antibodies Bv Crossing the blood brain barrier to treat diseases of the brain
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
US20260123608A1 (en) 2024-08-06 2026-05-07 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0144488A3 (en) 1980-08-11 1985-07-10 BAUSCH & LOMB INCORPORATED Apparatus for supporting and positioning the halves of a refractor
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
WO1992005801A1 (en) 1990-10-04 1992-04-16 University Of Virginia Alumni Patents Foundation Primate erythrocyte bound monoclonal antibody heteropolymers
DE69334275D1 (de) * 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1998021355A1 (en) * 1996-11-15 1998-05-22 Life Technologies, Inc. Mutants of green fluorescent protein
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
EP0954978B1 (en) * 1998-03-12 2011-11-30 VHsquared Limited New products comprising inactivated yeasts or moulds provided with active antibodies
US7083950B2 (en) † 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
IL154751A0 (en) * 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
WO2002012467A2 (en) 2000-08-04 2002-02-14 Incyte Genomics, Inc. Drug metabolizing enzymes
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US20030022240A1 (en) 2001-04-17 2003-01-30 Peizhi Luo Generation and affinity maturation of antibody library in silico
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
KR100945108B1 (ko) 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
JP4303105B2 (ja) * 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US6880232B2 (en) 2001-09-26 2005-04-19 Intel Corporation Method of making an electrical inductor using a sacrificial electrode
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US6755339B2 (en) † 2002-06-21 2004-06-29 Delphi Technologies, Inc. Fluxing apparatus for applying powdered flux
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
GB0218030D0 (en) 2002-08-02 2002-09-11 Minos Biosystems Multi-submit protein production system
GB0228210D0 (en) * 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
JP4906094B2 (ja) † 2004-01-16 2012-03-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド レセプターを活性化し得る融合ポリペプチド
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP1776383B1 (en) * 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
US20080184380A1 (en) 2004-10-22 2008-07-31 Therapeutic Human Polyclonals Inc. Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
LT2444424T (lt) 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
TWI404727B (zh) * 2006-01-25 2013-08-11 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 對偶基因排除
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
US7731969B1 (en) 2006-12-06 2010-06-08 Neoclone Biotechnology International, Llc Methods for developing and producing antigen-specific antibody-producing cells
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
WO2011072204A1 (en) 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
CN105861548B (zh) 2011-02-25 2020-01-10 瑞泽恩制药公司 Adam6小鼠
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
WO2014093908A2 (en) 2012-12-14 2014-06-19 Omt, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals

Also Published As

Publication number Publication date
US20100216974A1 (en) 2010-08-26
AU2005263994A1 (en) 2006-01-26
US9353179B2 (en) 2016-05-31
US20100197897A1 (en) 2010-08-05
JP2012005491A (ja) 2012-01-12
US20130345405A1 (en) 2013-12-26
EP4353819A3 (en) 2024-07-17
LT2311874T (lt) 2017-11-27
US20110118444A1 (en) 2011-05-19
EP1864998B2 (en) 2022-06-22
JP5888893B2 (ja) 2016-03-22
PL1776383T3 (pl) 2015-02-27
PL2311874T3 (pl) 2017-10-31
EP3272770A1 (en) 2018-01-24
SI2311874T1 (sl) 2017-12-29
ZA200801820B (en) 2013-05-29
BRPI0513577A (pt) 2008-05-06
WO2006008548A3 (en) 2006-06-01
EP2311874A3 (en) 2011-12-07
MX2007000921A (es) 2007-11-09
ZA201301416B (en) 2014-12-23
ES2635497T3 (es) 2017-10-04
US8921522B2 (en) 2014-12-30
KR20120079179A (ko) 2012-07-11
CN102659941B (zh) 2016-01-20
ES2523661T3 (es) 2014-11-28
CN102659940B (zh) 2022-07-05
EP1864998A3 (en) 2007-12-19
KR101422286B1 (ko) 2014-07-23
SI1776383T1 (sl) 2014-12-31
DK1864998T3 (da) 2014-01-13
EP1978032A3 (en) 2009-02-18
ES2440990T5 (es) 2022-10-25
DK1776383T3 (da) 2014-11-03
ES2440990T3 (es) 2014-01-31
AU2010212518B2 (en) 2013-03-14
PT1776383E (pt) 2014-12-02
US9346877B2 (en) 2016-05-24
KR20070050927A (ko) 2007-05-16
EP1776383A2 (en) 2007-04-25
EP2311874B1 (en) 2017-05-31
US20130344057A1 (en) 2013-12-26
CA2580336C (en) 2016-07-19
CN102659940A (zh) 2012-09-12
KR101457753B1 (ko) 2014-11-03
RU2007106728A (ru) 2008-08-27
EP3272770B1 (en) 2023-12-20
US20090285805A1 (en) 2009-11-19
SG188080A1 (en) 2013-03-28
EP1776383B1 (en) 2014-08-20
US10906970B2 (en) 2021-02-02
EP1864998A2 (en) 2007-12-12
KR20100133022A (ko) 2010-12-20
CA2580336A1 (en) 2006-01-26
JP2012024087A (ja) 2012-02-09
WO2006008548A2 (en) 2006-01-26
CY1115762T1 (el) 2017-01-25
KR20110102957A (ko) 2011-09-19
ZA200701186B (en) 2009-12-30
EP1978032A2 (en) 2008-10-08
PT2311874T (pt) 2017-08-25
MX338603B (es) 2016-04-22
EP2311874A2 (en) 2011-04-20
DK2311874T3 (en) 2017-08-28
KR101443473B1 (ko) 2014-09-22
AU2010212518A1 (en) 2010-09-16
EP1864998B1 (en) 2013-09-25
US8921524B2 (en) 2014-12-30
CY1119561T1 (el) 2018-03-07
HUE034335T2 (en) 2018-02-28
US20180244765A1 (en) 2018-08-30
CN102659941A (zh) 2012-09-12
JP5855381B2 (ja) 2016-02-09
JP2008512987A (ja) 2008-05-01
AU2005263994B2 (en) 2011-03-24
RU2398882C2 (ru) 2010-09-10
KR101151957B1 (ko) 2012-06-01
EP4353819A2 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
NO20201120A1 (no) Bindingsvirkninger
DK1864998T3 (da) Bindingsmolekyler
MA28989B1 (fr) MOLECULES Fc MODIFIEES
DK1838736T3 (da) Cripto-bindende molekyler
DK1633396T3 (da) CD20 bindende molekyler
DK1888113T3 (da) Tweak-bindende antistoffer
IS8397A (is) Meðferðarfræðilegar bindisameindir
EP1908601A4 (en) Binder
DE602006017100D1 (de) Luftgurtvorrichtung
PL1871804T3 (pl) Przeciwciała wiążące CCX-CKR2
EP1932681A4 (en) LEVER ARCH FILES
EP1829707A4 (en) STORAGE DEVICE
FI20050547A0 (fi) Side
FI20041026A0 (fi) Sidontalaite
FI20041350A0 (fi) Sidontalaite
SK4248U (sk) Prednakladač knižných blokov
FI20050927A0 (fi) Sidontalaite
FI20050009A0 (fi) Sidontalaite
FI20050718A0 (fi) Sidontalaite
FI20050349A0 (fi) Sidontalaite
UA10433S (uk) Буклетниця
UA12696S (uk) Книга
UA12402S (uk) Буклет
FIU20050104U0 (fi) Mäkihyppyside
SE0402621D0 (sv) Bokmärket BokOP